Table 3 |
||||||
|
Distribution of the SP-D Met11Thr genotype and allele frequencies and corresponding SP-D serum levels (median (95% CI)) |
||||||
|
N(%) of RA patients |
SP-D ng/ml* RA patients |
N(%) of controls |
SP-D ng/ml* Controls |
P-value ** |
Odds ratio *** |
|
|
|
||||||
|
Genotype: |
||||||
|
Met11/Met11 |
41 (27.3) |
724 (636; 1,123) |
152 (35.8) |
1,081 (996; 1,252) |
P = 0.16 |
1.0 (ref) |
|
Thr11/Thr11 |
27 (18.0) |
750 (603; 834) |
77 (18.1) |
896 (788; 955) |
1.3 (0.73; 2.4) |
|
|
Met11/Thr11 |
82 (54.7) |
660 (563; 761) |
196 (46.1) |
925 (845;1,023) |
1.6 (0.97; 2.6) |
|
|
Allele: |
||||||
|
Met11 |
164 (54.7) |
500 (58.8) |
P = 0.22 |
1.0 (ref) |
||
|
Thr11 |
136 (45.3) |
350 (41.2) |
1.2 (0.9;1.6) |
|||
|
|
||||||
|
* Kruskal-Wallis test: RA patients: P = 0.13 and controls: P = 0.0023 ** Distribution, P-value calculated using Fishers' Exact test *** Odds ratio (95% CI) calculated using logistic regression with health status as the dependent variable and genotype/allele, gender and age as independent variables. CI, confidence interval; SP-D, surfactant protein -D; RA, rheumatoid arthritis; Ref, reference |
||||||
|
Christensen et al. Arthritis Research & Therapy 2010 12:R39 doi:10.1186/ar2948 |
||||||
